Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The evolution of European guidelines: Changing the management of cholesterol levels.

Erhardt, Leif RW LU and Gotto, A (2006) In Atherosclerosis 185(Nov 22). p.12-20
Abstract
Cardiovascular disease (CVD) is the leading cause of death in Europe and the US. This paper reviews the evolution of the Joint European Societies' guidelines with respect to their lipid recommendations. We stress the importance of lowering lipid levels to, or below, the currently recommended goals and argue that patients' global risk for CVD, rather than baseline lipid levels, should direct the intensity of lipid-lowering treatment. However, the emphasis on near-term (i.e., in the next 10 years) global risk estimation may under-emphasize the importance of considering lifetime cardiovascular risk in treatment decisions. Although various guidelines' thresholds for treatment initiation and recommended goals differ, they are similar in the... (More)
Cardiovascular disease (CVD) is the leading cause of death in Europe and the US. This paper reviews the evolution of the Joint European Societies' guidelines with respect to their lipid recommendations. We stress the importance of lowering lipid levels to, or below, the currently recommended goals and argue that patients' global risk for CVD, rather than baseline lipid levels, should direct the intensity of lipid-lowering treatment. However, the emphasis on near-term (i.e., in the next 10 years) global risk estimation may under-emphasize the importance of considering lifetime cardiovascular risk in treatment decisions. Although various guidelines' thresholds for treatment initiation and recommended goals differ, they are similar in the theme of treating global risk. Most clinical trials have not identified a threshold of cholesterol level beyond which lowering cholesterol levels no longer provides cardiovascular benefit. An urgent call for action is needed to improve goal attainment in patients with or at risk for CVD. Improving access to risk-reducing treatments should be a priority. (c) 2005 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
risk, statins, cardiovascular diseases, factors, guidelines, hyperlipidemia
in
Atherosclerosis
volume
185
issue
Nov 22
pages
12 - 20
publisher
Elsevier
external identifiers
  • pmid:16309687
  • wos:000235541300002
  • scopus:30944448652
ISSN
1879-1484
DOI
10.1016/j.atherosclerosis.2005.10.001
language
English
LU publication?
yes
id
a3f4cfd2-96ee-4608-80e1-c94d34af96e5 (old id 147733)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16309687&dopt=Abstract
date added to LUP
2016-04-01 12:06:23
date last changed
2022-01-26 22:51:54
@article{a3f4cfd2-96ee-4608-80e1-c94d34af96e5,
  abstract     = {{Cardiovascular disease (CVD) is the leading cause of death in Europe and the US. This paper reviews the evolution of the Joint European Societies' guidelines with respect to their lipid recommendations. We stress the importance of lowering lipid levels to, or below, the currently recommended goals and argue that patients' global risk for CVD, rather than baseline lipid levels, should direct the intensity of lipid-lowering treatment. However, the emphasis on near-term (i.e., in the next 10 years) global risk estimation may under-emphasize the importance of considering lifetime cardiovascular risk in treatment decisions. Although various guidelines' thresholds for treatment initiation and recommended goals differ, they are similar in the theme of treating global risk. Most clinical trials have not identified a threshold of cholesterol level beyond which lowering cholesterol levels no longer provides cardiovascular benefit. An urgent call for action is needed to improve goal attainment in patients with or at risk for CVD. Improving access to risk-reducing treatments should be a priority. (c) 2005 Elsevier Ireland Ltd. All rights reserved.}},
  author       = {{Erhardt, Leif RW and Gotto, A}},
  issn         = {{1879-1484}},
  keywords     = {{risk; statins; cardiovascular diseases; factors; guidelines; hyperlipidemia}},
  language     = {{eng}},
  number       = {{Nov 22}},
  pages        = {{12--20}},
  publisher    = {{Elsevier}},
  series       = {{Atherosclerosis}},
  title        = {{The evolution of European guidelines: Changing the management of cholesterol levels.}},
  url          = {{http://dx.doi.org/10.1016/j.atherosclerosis.2005.10.001}},
  doi          = {{10.1016/j.atherosclerosis.2005.10.001}},
  volume       = {{185}},
  year         = {{2006}},
}